Since the first reported use of infliximab in 2001 for uveitis treatment, several new anti-TNF-α agents have been developed for the treatment of refractory uveitis (Muñoz-Fernández et al., 2001; Sfikakis et al., 2001). The gene discussed is TNF; the disease is uveitis.